West Pharmaceutical Services Inc (WST)

Return on assets (ROA)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 492,700 499,600 524,900 568,700 593,400 559,400 518,700 552,100 585,900 630,600 685,600 684,400 661,800 612,500 519,200 423,100 346,200 311,700 285,700 260,600
Total assets US$ in thousands 3,643,400 3,675,100 3,489,400 3,602,300 3,829,500 3,754,700 3,669,600 3,723,600 3,616,800 3,316,800 3,361,700 3,294,700 3,313,800 3,142,600 2,933,500 2,739,700 2,793,800 2,582,800 2,392,300 2,246,500
ROA 13.52% 13.59% 15.04% 15.79% 15.50% 14.90% 14.14% 14.83% 16.20% 19.01% 20.39% 20.77% 19.97% 19.49% 17.70% 15.44% 12.39% 12.07% 11.94% 11.60%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $492,700K ÷ $3,643,400K
= 13.52%

West Pharmaceutical Services Inc has shown varying levels of return on assets (ROA) over the past few years. The ROA has generally been increasing from around 11.60% in March 2020 to a peak of 20.77% in March 2022. This indicates that the company has been able to generate more income relative to its total assets during this period.

However, there has been a slight decline in ROA since the peak in March 2022, with the ratio decreasing to 13.52% by December 2024. This declining trend suggests that the company's ability to generate profits from its assets may be weakening or that its asset base is growing faster than its net income.

Overall, while West Pharmaceutical Services Inc has demonstrated a strong performance in terms of ROA in recent years, investors and analysts may want to monitor the trend closely to understand the factors driving the fluctuations and assess the company's future profitability potential.


Peer comparison

Dec 31, 2024

Company name
Symbol
ROA
West Pharmaceutical Services Inc
WST
13.52%
Carlisle Companies Incorporated
CSL
30.48%